132 related articles for article (PubMed ID: 25430799)
21. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.
Siraj AK; Prabhakaran S; Bavi P; Bu R; Beg S; Hazmi MA; Al-Rasheed M; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
Cancer; 2015 Jun; 121(11):1762-71. PubMed ID: 25712738
[TBL] [Abstract][Full Text] [Related]
22. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
23. Mutation spectrum in HNPCC in the Israeli population.
Goldberg Y; Porat RM; Kedar I; Shochat C; Sagi M; Eilat A; Mendelson S; Hamburger T; Nissan A; Hubert A; Kadouri L; Pikarski E; Lerer I; Abeliovich D; Bercovich D; Peretz T
Fam Cancer; 2008; 7(4):309-17. PubMed ID: 18389388
[TBL] [Abstract][Full Text] [Related]
24. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
Ferguson SE; Aronson M; Pollett A; Eiriksson LR; Oza AM; Gallinger S; Lerner-Ellis J; Alvandi Z; Bernardini MQ; MacKay HJ; Mojtahedi G; Tone AA; Massey C; Clarke BA
Cancer; 2014 Dec; 120(24):3932-9. PubMed ID: 25081409
[TBL] [Abstract][Full Text] [Related]
25. Genetic testing by cancer site: colon (nonpolyposis syndromes).
Senter L
Cancer J; 2012; 18(4):334-7. PubMed ID: 22846734
[TBL] [Abstract][Full Text] [Related]
26. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.
Mur P; Pineda M; Romero A; Del Valle J; Borràs E; Canal A; Navarro M; Brunet J; Rueda D; Ramón Y Cajal T; Lázaro C; Caldés T; Blanco I; Soto JL; Capellá G
Clin Genet; 2014 Mar; 85(3):260-6. PubMed ID: 23530899
[TBL] [Abstract][Full Text] [Related]
27. Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.
Stella A; Surdo NC; Lastella P; Barana D; Oliani C; Tibiletti MG; Viel A; Natale C; Piepoli A; Marra G; Guanti G
Clin Genet; 2007 Feb; 71(2):130-9. PubMed ID: 17250661
[TBL] [Abstract][Full Text] [Related]
28. A636P is associated with early-onset colon cancer in Ashkenazi Jews.
Guillem JG; Rapaport BS; Kirchhoff T; Kolachana P; Nafa K; Glogowski E; Finch R; Huang H; Foulkes WD; Markowitz A; Ellis NA; Offit K
J Am Coll Surg; 2003 Feb; 196(2):222-5. PubMed ID: 12595050
[TBL] [Abstract][Full Text] [Related]
29. Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment.
Jensen LH; Dysager L; Lindebjerg J; Kølvrå S; Byriel L; Crüger DG
Eur J Cancer; 2010 Jul; 46(10):1823-8. PubMed ID: 20417091
[TBL] [Abstract][Full Text] [Related]
30. Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey.
Barrow P; Green K; Clancy T; Lalloo F; Hill J; Evans DG
Clin Genet; 2015 Jun; 87(6):517-24. PubMed ID: 25652327
[TBL] [Abstract][Full Text] [Related]
31. The nonsense mutation MSH2 c.2152C>T shows a founder effect in Portuguese Lynch syndrome families.
Pinheiro M; Francisco I; Pinto C; Peixoto A; Veiga I; Filipe B; Santos C; Maia S; Silva J; Pinto P; Santos R; Claro I; Lage P; Lopes P; Ferreira S; Rosa I; Fonseca R; Rodrigues P; Henrique R; Chaves P; Pereira AD; Brandão C; Albuquerque C; Teixeira MR
Genes Chromosomes Cancer; 2019 Sep; 58(9):657-664. PubMed ID: 30968502
[TBL] [Abstract][Full Text] [Related]
32. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome.
Raskin L; Schwenter F; Freytsis M; Tischkowitz M; Wong N; Chong G; Narod SA; Levine DA; Bogomolniy F; Aronson M; Thibodeau SN; Hunt KS; Rennert G; Gallinger S; Gruber SB; Foulkes WD
Clin Genet; 2011 Jun; 79(6):512-22. PubMed ID: 21155762
[TBL] [Abstract][Full Text] [Related]
33. A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer.
Kedar I; Walsh L; Levi GR; Lieberman S; Shtaya AA; Nathan SN; Lagovsky I; Tomashov-Matar R; Goldenberg M; Basel-Salmon L; Katz L; Aleme O; Peretz TY; Hubert A; Rothstein D; Castellvi-Bel S; Walsh T; King MC; Pritchard CC; Levi Z; Half E; Laish I; Goldberg Y
Fam Cancer; 2022 Apr; 21(2):181-188. PubMed ID: 33837488
[TBL] [Abstract][Full Text] [Related]
34. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.
Mukherjee B; Rennert G; Ahn J; Dishon S; Lejbkowicz F; Rennert HS; Shiovitz S; Moreno V; Gruber SB
Gastroenterology; 2011 Jun; 140(7):1919-26. PubMed ID: 21419771
[TBL] [Abstract][Full Text] [Related]
35. Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome.
Dewanwala A; Chittenden A; Rosenblatt M; Mercado R; Garber JE; Syngal S; Stoffel EM
Fam Cancer; 2011 Sep; 10(3):549-56. PubMed ID: 21567236
[TBL] [Abstract][Full Text] [Related]
36. Modified capture-recapture estimates of the number of families with Lynch syndrome in Central Ohio.
Ranola JMO; Pearlman R; Hampel H; Shirts BH
Fam Cancer; 2019 Jan; 18(1):67-73. PubMed ID: 30019097
[TBL] [Abstract][Full Text] [Related]
37. Gut microbial signatures are associated with Lynch syndrome (LS) and cancer history in Druze communities in Israel.
Naddaf R; Carasso S; Reznick-Levi G; Hasnis E; Qarawani A; Maza I; Gefen T; Half EE; Geva-Zatorsky N
Sci Rep; 2023 Nov; 13(1):20677. PubMed ID: 38001152
[TBL] [Abstract][Full Text] [Related]
38. Genetic testing for Lynch syndrome: family communication and motivation.
Leenen CH; Heijer Md; van der Meer C; Kuipers EJ; van Leerdam ME; Wagner A
Fam Cancer; 2016 Jan; 15(1):63-73. PubMed ID: 26446592
[TBL] [Abstract][Full Text] [Related]
39. Lynch syndrome in South America: past, present and future.
Vaccaro CA; Sarroca C; Rossi B; Lopez-Kostner F; Dominguez M; Calo NC; Cutait R; Valle AD; Nuñez L; Neffa F; Alvarez K; Gonzalez ML; Kalfayan P; Lynch HT; Church J
Fam Cancer; 2016 Jul; 15(3):437-45. PubMed ID: 27007491
[TBL] [Abstract][Full Text] [Related]
40. Bayesian modeling for genetic anticipation in presence of mutational heterogeneity: a case study in Lynch syndrome.
Boonstra PS; Mukherjee B; Taylor JM; Nilbert M; Moreno V; Gruber SB
Biometrics; 2011 Dec; 67(4):1627-37. PubMed ID: 21627626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
